Zimmer Biomet Holdings (ZBH) Cost of Revenue (2009 - 2026)

Zimmer Biomet Holdings has reported Cost of Revenue for 18 years, with the latest figure at $576.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 4.8% year-over-year to $576.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (up 13.07% YoY), and the FY2025 full-year result was $2.5 billion, up 13.81% from the prior year.
• Cost of Revenue for Q1 2026 stood at $576.2 million, down from $792.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $792.4 million in Q4 2025, with the low at $488.2 million in Q3 2022.
• Average Cost of Revenue over 5 years is $550.8 million, with a median of $538.6 million recorded in 2024.
• Year-over-year, Cost of Revenue retreated 3.02% in 2022 and jumped 35.06% in 2025.
• Tracing ZBH's Cost of Revenue over 5 years: stood at $520.3 million in 2022, then gained by 3.56% to $538.8 million in 2023, then grew by 8.89% to $586.7 million in 2024, then jumped by 35.06% to $792.4 million in 2025, then declined by 27.28% to $576.2 million in 2026.
• The last three Cost of Revenue figures came in at $576.2 million (Q1 2026), $792.4 million (Q4 2025), and $559.3 million (Q3 2025), per Business Quant data.

Peer Comparison